By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The UK technology development firm Angle said today that Parsortix, a cancer diagnostics company in which it owns a 90 percent stake, will partner with the Paterson Institute for Cancer Research, based at the University of Manchester, UK, to develop circulating tumor cell-based technology for lung cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.